Immunothrombosis and COVID-19 ‒ a nested post-hoc analysis from a 3186 patient cohort in a Latin American public reference hospital.

OBJECTIVE: COVID-19 is associated with an elevated risk of thromboembolism and excess mortality. Difficulties with best anticoagulation practices and their implementation motivated the current analysis of COVID-19 patients who developed Venous Thromboembolism (VTE). METHOD: This is a post-hoc analysis of a COVID-19 cohort, described in an economic study already published. The authors analyzed a subset of patients with confirmed VTE. We described the characteristics of the cohort, such as demographics, clinical status, and laboratory results. We tested differences amid two subgroups of patients, those with VTE or not, with the competitive risk Fine and Gray model. RESULTS: Out of 3186 adult patients with COVID-19, 245 (7.7%) were diagnosed with VTE, 174 (5.4%) of them during admission to the hospital. Four (2.3% of these 174) did not receive prophylactic anticoagulation and 19 (11%) discontinued anticoagulation for at least 3 days, resulting in 170 analyzed. During the first week of hospitalization, the laboratory most altered results were C-reactive protein and D-dimer. Patients with VTE were more critical, had a higher mortality rate, worse SOFA score, and, on average, 50% longer hospital stay. CONCLUSION: Proven VTE incidence in this severe COVID-19 cohort was 7.7%, despite 87% of them complying completely with VTE prophylaxis. The clinician must be aware of the diagnosis of VTE in COVID-19, even in patients receiving proper prophylaxis.

Immunothrombosis and COVID-19 ‒ a nested post-hoc analysis from a 3186 patient cohort in a Latin American public reference hospital

Abstract Objective COVID-19 is associated with an elevated risk of thromboembolism and excess mortality. Difficulties with best anticoagulation practices and their implementation motivated the current analysis of COVID-19 patients who developed Venous Thromboembolism (VTE). Method This is a post-hoc analysis of a COVID-19 cohort, described in an economic study already published. The authors analyzed a subset of patients with confirmed VTE. We described the characteristics of the cohort, such as demographics, clinical status, and laboratory results. We tested differences amid two subgroups of patients, those with VTE or not, with the competitive risk Fine and Gray model. Results Out of 3186 adult patients with COVID-19, 245 (7.7%) were diagnosed with VTE, 174 (5.4%) of them during admission to the hospital. Four (2.3% of these 174) did not receive prophylactic anticoagulation and 19 (11%) discontinued anticoagulation for at least 3 days, resulting in 170 analyzed. During the first week of hospitalization, the laboratory most altered results were C-reactive protein and D-dimer. Patients with VTE were more critical, had a higher mortality rate, worse SOFA score, and, on average, 50% longer hospital stay. Conclusion Proven VTE incidence in this severe COVID-19 cohort was 7.7%, despite 87% of them complying completely with VTE prophylaxis. The clinician must be aware of the diagnosis of VTE in COVID-19, even in patients receiving proper prophylaxis.

Use and misuse of biomarkers and the role of D-dimer and C-reactive protein in the management of COVID-19: A post-hoc analysis of a prospective cohort study.

OBJECTIVE: Coronavirus disease 2019 (COVID-19) is associated with high mortality among hospitalized patients and incurs high costs. Severe acute respiratory syndrome coronavirus 2 infection can trigger both inflammatory and thrombotic processes, and these complications can lead to a poorer prognosis. This study aimed to evaluate the association and temporal trends of D-dimer and C-reactive protein (CRP) levels with the incidence of venous thromboembolism (VTE), hospital mortality, and costs among inpatients with COVID-19. METHODS: Data were extracted from electronic patient records and laboratory databases. Crude and adjusted associations for age, sex, number of comorbidities, Sequential Organ Failure Assessment score at admission, and D-dimer or CRP logistic regression models were used to evaluate associations. RESULTS: Between March and June 2020, COVID-19 was documented in 3,254 inpatients. The D-dimer level ≥4,000 ng/mL fibrinogen equivalent unit (FEU) mortality odds ratio (OR) was 4.48 (adjusted OR: 1.97). The CRP level ≥220 mg/dL OR for death was 7.73 (adjusted OR: 3.93). The D-dimer level ≥4,000 ng/mL FEU VTE OR was 3.96 (adjusted OR: 3.26). The CRP level ≥220 mg/dL OR for VTE was 2.71 (adjusted OR: 1.92). All these analyses were statistically significant (p<0.001). Stratified hospital costs demonstrated a dose-response pattern. Adjusted D-dimer and CRP levels were associated with higher mortality and doubled hospital costs. In the first week, elevated D-dimer levels predicted VTE occurrence and systemic inflammatory harm, while CRP was a hospital mortality predictor. CONCLUSION: D-dimer and CRP levels were associated with higher hospital mortality and a higher incidence of VTE. D-dimer was more strongly associated with VTE, although its discriminative ability was poor, while CRP was a stronger predictor of hospital mortality. Their use outside the usual indications should not be modified and should be discouraged.

Perception of usefulness of laboratory tests ordering by internal medicine residents in ambulatory setting: A single-center prospective cohort study.

The demand for high value health care uncovered a steady trend in laboratory tests ordering and inappropriate testing practices. Residents' training in laboratory ordering practice provides an opportunity for quality improvement. We collected information on demographics, the main reason for the appointment, preexisting medical conditions and presence of co-morbidities from first-visit patients to the internal medicine outpatient service of our university general hospital. We also collected information on all laboratory tests ordered by the attending medical residents. At a follow-up visit, we recorded residents' subjective perception on the usefulness of each ordered laboratory test for the purposes of diagnosis, prognosis, treatment or screening. We observed that 17.3% of all ordered tests had no perceived utility by the attending resident. Tests were usually ordered to exclude differential diagnoses (26.7%) and to help prognosis estimation (19.1%). Age and co-morbidity influenced the chosen category to legitimate usefulness of tests ordering. This study suggests that clinical objectives (diagnosis, prognosis, treatment or prevention) as well as personalization to age and previous health conditions should be considered before test ordering to allow a more appropriate laboratory tests ordering, but further studies are necessary to examine this framework beyond this medical training scenario.

Use and misuse of biomarkers and the role of D-dimer and C-reactive protein in the management of COVID-19: A post-hoc analysis of a prospective cohort study

OBJECTIVE: Coronavirus disease 2019 (COVID-19) is associated with high mortality among hospitalized patients and incurs high costs. Severe acute respiratory syndrome coronavirus 2 infection can trigger both inflammatory and thrombotic processes, and these complications can lead to a poorer prognosis. This study aimed to evaluate the association and temporal trends of D-dimer and C-reactive protein (CRP) levels with the incidence of venous thromboembolism (VTE), hospital mortality, and costs among inpatients with COVID-19. METHODS: Data were extracted from electronic patient records and laboratory databases. Crude and adjusted associations for age, sex, number of comorbidities, Sequential Organ Failure Assessment score at admission, and D-dimer or CRP logistic regression models were used to evaluate associations. RESULTS: Between March and June 2020, COVID-19 was documented in 3,254 inpatients. The D-dimer level ≥4,000 ng/mL fibrinogen equivalent unit (FEU) mortality odds ratio (OR) was 4.48 (adjusted OR: 1.97). The CRP level ≥220 mg/dL OR for death was 7.73 (adjusted OR: 3.93). The D-dimer level ≥4,000 ng/mL FEU VTE OR was 3.96 (adjusted OR: 3.26). The CRP level ≥220 mg/dL OR for VTE was 2.71 (adjusted OR: 1.92). All these analyses were statistically significant (p<0.001). Stratified hospital costs demonstrated a dose-response pattern. Adjusted D-dimer and CRP levels were associated with higher mortality and doubled hospital costs. In the first week, elevated D-dimer levels predicted VTE occurrence and systemic inflammatory harm, while CRP was a hospital mortality predictor. CONCLUSION: D-dimer and CRP levels were associated with higher hospital mortality and a higher incidence of VTE. D-dimer was more strongly associated with VTE, although its discriminative ability was poor, while CRP was a stronger predictor of hospital mortality. Their use outside the usual indications should not be modified and should be discouraged.

A continuous fall of PSA use for prostate cancer screening among Brazilian doctors since 2001. Good or bad notice?

ABSTRACT Purpose: To evaluate the trend of use of Prostate Specific Antigen (PSA) for screening of prostate cancer (PC) among Brazilian doctors, from the beginning of its regular availability in clinical laboratories. Material and Methods: A serial cross-sectional study was performed using data obtained from a large database between 1997 and 2016. The general PSA screening trend during this period, adjusted for the total number of exams performed in men, was analyzed. Time-series analysis was performed through observation of the general regression curve using the generalized least squares method, and the impact of the recommendations was assessed with autoregressive integrated moving average (ARIMA) models. Results: During the period studied 2,521,383 PSA determinations were done. The age of the participants ranged from 21 to 111 years, with an average of 56.7 ± 22.7 years. The relative number of PSA tests/100.000 exams in males showed a constant reduction since 2001, and this trend was more evident in the group aged 55-69 years. Although statistically significant, the impact of reduced PSA screening after the 2012 USPSTF publication was clinically irrelevant. Conclusions: Our results indicated a continuous reduction in the use of PSA screening over time, regardless of the publication of recommendations or clinical guidelines. The fact that this trend was more pronounced among those with a greater benefit potential (55-69 years), relative to groups with a greater damage potential due to overdiagnosis and overtreatment (aged >74 years and <40 years), is a matter of concern. Follow-up studies of these trends are advisable.

A continuous fall of PSA use for prostate cancer screening among Brazilian doctors since 2001. Good or bad notice?

PURPOSE: To evaluate the trend of use of Prostate Specifi c Antigen (PSA) for screening of prostate cancer (PC) among Brazilian doctors, from the beginning of its regular availability in clinical laboratories. MATERIAL AND METHODS: A serial cross-sectional study was performed using data obtained from a large database between 1997 and 2016. The general PSA screening trend during this period, adjusted for the total number of exams performed in men, was analyzed. Time-series analysis was performed through observation of the general regression curve using the generalized least squares method, and the impact of the recommendations was assessed with autoregressive integrated moving average (ARIMA) models. RESULTS: During the period studied 2,521,383 PSA determinations were done. The age of the participants ranged from 21 to 111 years, with an average of 56.7 ± 22.7 years. The relative number of PSA tests/100.000 exams in males showed a constant reduction since 2001, and this trend was more evident in the group aged 55-69 years. Although statistically signifi cant, the impact of reduced PSA screening after the 2012 USPSTF publication was clinically irrelevant. CONCLUSIONS: Our results indicated a continuous reduction in the use of PSA screening over time, regardless of the publication of recommendations or clinical guidelines. The fact that this trend was more pronounced among those with a greater benefi t potential (55-69 years), relative to groups with a greater damage potential due to overdiagnosis and overtreatment (aged >74 years and < 40 years), is a matter of concern. Follow-up studies of these trends are advisable.

Interferon lambda and hepatitis C virus core protein polymorphisms associated with liver cancer.

BACKGROUND: Hepatitis C virus (HCV) infection is often persistent and gradually advances from chronic hepatitis to liver cirrhosis and hepatocellular carcinoma (HCC). Worldwide, hepatocellular carcinoma is the fifth most common neoplasm. METHOD OF STUDY: the Interferon lambda (IFNL) polymorphisms genotypes (rs8099917, rs12979860 and rs12980275) and the presence of mutations in HCV core protein were analyzed in 59 patients with HCC, and also in 50 cirrhotic patients (without HCC). RESULTS: the rs12980275-AG genotype was associated with HCC on age-adjusted analysis (OR 2.42, 95% CI 1.03-5.69, P=0.043). Core substitutions R70Q and L91M were mainly found in genotype 1b isolates. Furthermore, a borderline level of statistical significance association was found among the presence of amino acid Glutamine (Q) in the position 70 and IFNL3 genotype AG (P=0.054). CONCLUSIONS: the screening of these polymorphisms and functional studies would be useful in clinical practice for identifying groups at high risk of HCC development.

Rational use of blood calcium determinations.

CONTEXT AND OBJECTIVE: This study was motivated by the recent excessive increase in requests for blood calcium determinations and laboratory tests in general, in the Hospital das Clínicas complex of Faculdade de Medicina, Universidade de São Paulo (HCFMUSP). Its aim was to suggest rules for the determination of total and ionized calcium in our intensive care units, emergency department, wards and outpatient services, thus contributing towards improving the quality of medical care and achieving more appropriate use of human and financial resources. DESIGN AND SETTING: Critical analysis on clinical and laboratory data and the pertinent scientific literature, conducted by the study group for rational clinical laboratory use, which is part of the Central Laboratory Division, HCFMUSP. METHODS: The study group reviewed scientific publications, statistics and clinical and laboratory data concerning requests for total and ionized calcium determinations in the settings of intensive care units, emergency department, wards and outpatient services. RESULTS: From this critical analysis, clinical decision flow diagrams aimed at providing guidance for ordering these tests were constructed. CONCLUSIONS: Use of the proposed flow diagrams may help to limit the numbers of inappropriate requests for ionized and total calcium determinations, with consequent reductions in the number of tests, risks to patients and unnecessary costs.

Rational use of blood calcium determinations / Uso racional da dosagem de cálcio no sangue

CONTEXT AND OBJECTIVE: This study was motivated by the recent excessive increase in requests for blood calcium determinations and laboratory tests in general, in the Hospital das Clínicas complex of Faculdade de Medicina, Universidade de São Paulo (HCFMUSP). Its aim was to suggest rules for the determination of total and ionized calcium in our intensive care units, emergency department, wards and outpatient services, thus contributing towards improving the quality of medical care and achieving more appropriate use of human and financial resources. DESIGN AND SETTING: Critical analysis on clinical and laboratory data and the pertinent scientific literature, conducted by the study group for rational clinical laboratory use, which is part of the Central Laboratory Division, HCFMUSP. METHODS: The study group reviewed scientific publications, statistics and clinical and laboratory data concerning requests for total and ionized calcium determinations in the settings of intensive care units, emergency department, wards and outpatient services. RESULTS: From this critical analysis, clinical decision flow diagrams aimed at providing guidance for ordering these tests were constructed. CONCLUSIONS: Use of the proposed flow diagrams may help to limit the numbers of inappropriate requests for ionized and total calcium determinations, with consequent reductions in the number of tests, risks to patients and unnecessary costs. .

CONTEXTO E OBJETIVO: Este trabalho foi motivado pelo recente aumento excessivo de solicitações de dosagem de cálcio no sangue, assim como de exames laboratoriais em geral, no complexo do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP). Seu objetivo foi sugerir regras para a determinação de cálcio total e iônico nas nossas unidades de terapia intensiva, pronto-socorro, enfermarias e ambulatórios e contribuir para a melhoria da qualidade da assistência médica, com utilização mais adequada dos recursos humanos e financeiros. TIPO DO ESTUDO E LOCAL: Análise crítica de dados clínicos, laboratoriais e da literatura médica pertinente, realizada pelo grupo de estudos para o uso racional do laboratório clínico, vinculado à Divisão de Laboratório Central do HCFMUSP. MÉTODOS: O grupo de estudos reviu publicações científicas, estatísticas e dados clínico-laboratoriais relativos às solicitações de cálcio total e iônico nos ambientes das unidades de terapia intensiva, prontos-socorros, enfermarias e ambulatórios. RESULTADOS: A partir dessa análise crítica, foram construídos fluxogramas de decisão clínica que visam orientar a requisição desses testes. CONCLUSÕES: A utilização dos fluxogramas propostos pode ajudar a limitar a solicitação inadequada das dosagens de cálcio total e iônico, com consequente redução do número de exames, de riscos para os pacientes e de custos desnecessários. .

Practical aspects of the use of FMEA tool in clinical laboratory risk management / Aspectos práticos da utilização da ferramenta FMEA na gestão de riscos do laboratório clínico

INTRODUCTION: This paper presents the failure modes and effects analysis (FMEA) tool in a clinical laboratory through the introduction of new technology for blood gas and serum ionized calcium in multi-parameter analyzers such as Point of Care Testing (POCT). OBJECTIVE: To present FMEA as a tool for risk managing and improvement with the introduction of new technologies in a public laboratory. METHODS: The change of multiparameter gas analyzer type POCT was defined and described as a process. Subsequently, the criteria were presented to the risk assessment and its quantification. We studied the failure modes that might occur in this process. We established three action plans involving improvements to be made in the technological change. FMEA was applied in two stages: at the beginning of the project and after the implementation of the proposed measures. RESULTS: The first plan involved administrative measures related to the bidding process; the second preventive action involved the possibility of which supplier would win the bid by studying the efficiency of the analyzer and its impact on productivity; the third set of actions was directed to improvements in the relationship with the clinical staff in order to minimize occasional complaints. The last actions referred to employing new employees to meet the growing demand. CONCLUSION: FMEA proved to be a reliable tool for performance improvement, which proactively identifies, prioritizes and mitigates patient risks.

INTRODUÇÃO: O artigo apresenta a ferramenta de análise do modo e do efeito de falhas (FMEA) dentro de um laboratório clínico por meio da introdução de nova tecnologia para gasometria e cálcio iônico sérico em analisadores multiparâmetros do tipo testes laboratoriais remotos (TLR) ou point of care testing (POCT). OBJETIVO: Apresentar a FMEA como ferramenta de gestão de riscos e de melhoria em um laboratório público ao introduzir novas tecnologias. MÉTODOS: A mudança de analisadores de gases multiparâmetros do tipo POCT foi definida e descrita como um processo. A seguir, foram apresentados os critérios para a avaliação dos riscos e a sua quantificação. Foram estudados os modos de falha pelos quais algo poderia falhar nos componentes desse processo. Estabeleceram-se três planos de ações que envolviam melhorias a serem introduzidas na mudança de tecnologia. A FMEA foi aplicada em dois momentos: no início do projeto e após a implantação das medidas propostas. RESULTADOS: O primeiro plano envolveu medidas administrativas vinculadas ao processo licitatório; a segunda ação preventiva envolveu a possibilidade de qual fornecedor venceria a licitação, estudando-se a eficiência do analisador e seu impacto na produtividade; o terceiro conjunto de ações foi dirigido às melhorias no relacionamento com o corpo clínico para minimizar as eventuais reclamações. As últimas ações referiram-se à contratação de novos funcionários para atender à demanda crescente. CONCLUSÃO: A FMEA revelou-se um instrumento de melhoria de desempenho para o laboratório, que de maneira proativa identifica, prioriza e mitiga os riscos do paciente.

Avaliação da interferência do ácido ascórbico na detecção da glicosúria / Evaluation of ascorbic acid interference in the detection of glycosuria

INTRODUÇÃO: O ácido ascórbico (vitamina C) é comumente ingerido como suplemento vitamínico. É uma vitamina hidrossolúvel, excretada pela urina e pode interferir nos ensaios laboratoriais, como nas reações de oxirredução para detecção da glicosúria. OBJETIVO: Este trabalho tem como objetivo avaliar a interferência do ácido ascórbico na detecção de glicosúria pelo método de química seca por meio do uso de tiras reagentes. MATERIAIS E MÉTODOS: Amostras de urina foram avaliadas no analisador da marca Clinitek Atlas (Siemens Healthcare Diagnostics Inc., EUA). Foram selecionadas quatro amostras de urina com diferentes concentrações de glicose: 100 mg/dl, 250 mg/dl, 500 mg/dl e 1.000 mg/dl. Para cada concentração de glicose foram criadas cinco alíquotas, adicionando-se uma solução de ácido ascórbico 200 mg/dl, suficiente para obter uma concentração final de ácido ascórbico de 20 mg/dl no primeiro tubo, de 50 mg/dl no segundo tubo, de 270 mg/dl no terceiro tubo, de 1.000 mg/dl no quarto tubo e de 2.000 mg/dl no quinto tubo. Após essa adição, as amostras foram novamente avaliadas no analisador Clinitek Atlas. RESULTADOS: Nas amostras com concentração de 20 mg/dl de ácido, não se evidenciou interferência. Nas concentrações iguais e acima de 50 mg/dl, a interferência do ácido ascórbico se fez presente, sendo que o fato foi caracterizado pelos resultados falso negativos para detecção da glicose urinária. CONCLUSÃO: Os resultados demonstraram a interferência do ácido ascórbico no método da química seca (tiras reagentes), subestimando o nível de glicose urinária.

INTRODUCTION: Ascorbic acid (vitamin C) is commonly used as a vitamin supplement. It is a water soluble vitamin, which is excreted through urine and may interfere in laboratory tests as well as redox reactions for urinary glucose detection. OBJECTIVE: This study aims to assess ascorbic acid interference in glycosuria detection by dry chemistry method (reagent strips). MATERIAL AND METHODS: Urine samples were evaluated by using Clinitek Atlas chemistry analyzer (Siemens Healthcare Diagnostics Inc., USA). Four urine samples with different glucose concentrations were selected: 100 mg/dl, 250 mg/dl, 500 mg/dl and > 1,000 mg/dl. 5 aliquots were created for each glucose concentration and a solution of ascorbic acid 200 mg/dl was added, sufficient to obtain a final ascorbic acid concentration of 20 mg/dl in the first tube, 50 mg/dl in the second tube, 270 mg/dl in the third tube, 1,000 mg/dl the fourth tube, and 2,000 mg/dl in the fifth tube. After the addition of ascorbic acid, the samples were reassessed by using Clinitek Atlas chemistry analyzer. RESULTS: There was no interference at concentrations of 20 mg/dl. However, there was ascorbic acid interference at concentrations higher than or equal to 50 mg/dl, which was characterized by false-negative results for urinary glucose detection. CONCLUSION: The results corroborated the interference of ascorbic acid in dry chemistry method (reagent strips) inasmuch as it underestimates urinary glucose levels.

A utilidade dos indicadores da qualidade no gerenciamento de laboratórios clínicos / Usefulness of quality indicators in the management of clinical laboratories

O uso dos indicadores da qualidade vem sendo valorizado na gestão dos laboratórios clínicos para otimizar a qualificação e a quantificação das falhas nos diferentes processos laboratoriais, bem como para auxiliar a implantação de medidas corretivas e preventivas e apontar a eficácia das ações tomadas. O objetivo deste trabalho é discorrer sobre a evolução da qualidade na área da saúde, com ênfase na área laboratorial. Alguns indicadores laboratoriais citados na literatura nas fases pré-analítica, analítica e pós-analítica também são apresentados e discutidos neste artigo. Por fim, destaca-se a experiência brasileira do Programa de Indicadores Laboratoriais desenvolvido pela Sociedade Brasileira de Patologia Clínica/Medicina Laboratorial (SBPC/ML) em parceria com a Control-Lab e o projeto Model of Quality Indicator, em fase de desenvolvimento pela International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

The use of quality indicators has been appreciated in laboratory management so as to optimize quality and error quantification in several laboratory processes. Furthermore, it assists in the implementation of preventive and corrective measures and it shows their corresponding efficiency. The objective of the present study is to discuss the evolution of quality, mainly in the laboratory area, focusing on the importance of quality indicators in laboratory management. Some pre-analytical, analytical and post-analytical laboratory indicators are also presented and discussed in this work. Finally, we highlight the Brazilian initiative in the Laboratory Indicator Program developed by the Brazilian Society of Clinical Pathology and Laboratory Medicine (SBPC/ML) in partnership with Control-Lab and the Model of Quality Indicator project, which has been developed by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

O laboratório clínico livre de mercúrio / The clinical laboratory free of mercury

INTRODUÇÃO: No último século, os níveis de mercúrio no meio ambiente triplicaram, aumentado o risco de contaminação do ser humano. No ambiente, o mercúrio contamina os lençóis freáticos, bem como rios e mares e entra na cadeia alimentar pela ingestão de peixes contaminados. No organismo, afeta o sistema nervoso central (SNC). A exposição aguda, por inalação de vapores de mercúrio, acarreta astenia, fadiga, anorexia, perda de peso e perturbações gastrointestinais. O diagnóstico da contaminação é realizado pela análise em amostras de cabelo/sangue. A substituição dos equipamentos contendo mercúrio utilizados em serviços de saúde é procedimento fundamental para a redução dos riscos ocupacionais e ambientais. OBJETIVO: Descrever o processo de implantação do programa de "Mercúrio Zero" na Divisão de Laboratório Central do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (DLC/HC-FMUSP). MÉTODOS: O projeto foi desenvolvido em um período de três anos (2008-2010). Na elaboração do projeto, foram definidos planos de ações, incluindo um programa de treinamento e capacitação de uma equipe de trabalho responsável pela execução do processo de substituição dos equipamentos e reagentes. RESULTADOS: Ao final do projeto de implantação, a DLC/HC-FMUSP foi laureada com uma menção honrosa pelo programa Mercúrio Zero do Ministério do Trabalho e Emprego (MTE) por ter cumprido as exigências. CONCLUSÃO: Um ambiente laboratorial livre de mercúrio requer compromisso da alta direção e planejamento com ações consistentes, além de maturidade e conscientização de todos os colaboradores acerca do risco representado pelo mercúrioà saúde e ao meio ambiente.

INTRODUCTION: Over the last century, mercury levels in the environment have tripled, increasing the risk of human contamination. Hence, it pollutes groundwater, rivers and seas, and it enters the food chain through the ingestion of contaminated fish. It affects the central nervous system and the inhalation of mercury vapors cause asthenia, fatigue, anorexia, weight loss and gastrointestinal disturbances. The contamination detection is carried out through hair and blood sample analysis. The replacement of mercury-containing equipment used in health services is crucial in order to reduce environmental and occupational hazards. OBJECTIVE: To describe the implementation of "Zero Mercury" program at the Central Laboratory Division of University of São Paulo Medical School Hospital - CLD/USP-MSH (Divisão de Laboratório Central do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo [DLC/HC-FMUSP]). METHODS: The project was developed within the period of three years (2008-2010). During its elaboration, the action plans were defined, including a training program for the team responsible for the implementation of equipment and reagent replacement. RESULTS: By the end of the project, CLD/USP-MSH received an honorable mention by the Brazilian Ministry of Labor and Employment for the fulfillment of "Mercury Zero" program requirements. CONCLUSION: A mercury-free laboratory environment requires managerial commitment, a consistent action plan and staff awareness of health and environmental risks.

A importância da qualidade da água reagente no laboratório clínico / The importance of water quality in clinical laboratory reagent

A água é um reagente utilizado na maioria dos testes laboratoriais e por isso deve seguir um padrão de controle de qualidade rigoroso. O fornecimento urbano de água apresenta moléculas orgânicas, íons inorgânicos, partículas, coloides, gases, bactérias e seus produtos, que podem alterar os resultados dos exames laboratoriais e causar eventuais erros e falhas mecânicas em equipamentos analíticos. Para remover essas impurezas, é necessário recorrer a uma combinação de tecnologias de purificação. Há várias organizações que especificam normas sobre a água reagente, a fim de minimizar sua interferência nos ensaios laboratoriais. A maioria dos laboratórios utiliza as normas estabelecidas pelo Clinical and Laboratory Standards Institute (CLSI) que classifica a água em: clinical laboratory reagent water (CLRW), special reagent water (SRW) e instrumental feed water (IFW). O monitoramento da qualidade é realizado pela determinação de resistividade, condutividade, carbono orgânico total (TOC), controle microbiológico e endotoxinas. Os parâmetros são avaliados de acordo com a periodicidade estabelecida pela norma utilizada. Neste artigo, discutem-se a importância da água utilizada nos procedimentos laboratoriais, o controle da qualidade e as interferências nos ensaios laboratoriais.

Water is a reagent used in most laboratory tests and, therefore, must follow stringent quality control standards. The urban water supply has organic molecules, inorganic ions, particles, colloids, gases, bacteria and their products, which may alter laboratory test results and cause occasional errors and mechanical failures in diagnostic equipment. To remove these impurities, it is necessary to use a combination of purification technologies. There are several organizations that specify reagent water standards to minimize its interference in laboratory assays. Most laboratories set standards established by the Clinical and Laboratory Standards Institute (CLSI), which classifies the type of water as follows: clinical laboratory reagent water (CLRW), special reagent water (SRW) and instrumental feed water (IFW). The quality monitoring is performed by means of assessing the resistivity, conductivity, total organic carbon (TOC), microbial control and endotoxins. The parameters are evaluated in accordance with the frequency determined by the standard used. In this article we discuss the importance of water employed in laboratory procedures, its quality control and its interference in laboratory assays.

Como colocar em prática o Plano de Atendimento às Emergências (PAE) no laboratório clínico / How to implement the Plan of Care for Emergencies (LAP) in the clinical laboratory

INTRODUÇÃO: A situação socioeconômica e ambiental na qual os laboratórios clínicos vivem, aliada aos riscos ampliados do negócio nos dias atuais, exige dos dirigentes a elaboração de um plano de segurança para situações de catástrofes. OBJETIVO: Esse plano é útil para garantir a continuidade do negócio e sua recuperação após a crise. MÉTODO: O Plano de Atendimento à Emergência (PAE) é apresentado como um conjunto de procedimentos estruturados para a obtenção de respostas rápidas, adestradas e eficientes em situações de emergência no laboratório. CONCLUSÃO: Ele visa prevenir ou mitigar as eventuais consequências adversas para segurança, saúde e meio ambiente no âmbito laboratorial. RESULTADO: Este artigo discute a aplicabilidade, as responsabilidades, a elaboração e a manutenção, assim como suas implicações na rotina laboratorial.

INTRODUCTION: Nowadays, the environmental and socioeconomic contexts in which clinical laboratories are set, coupled with increased business risks, require the formulation of an emergency care plan in case of natural disasters. OBJECTIVE: This plan is useful to ensure business continuity and recovery after crisis. METHOD: The Emergency Care Plan (PAE) is presented as a structured set of procedures for obtaining rapid, efficient and trained responses in emergency situations. CONCLUSION: It aims at preventing or mitigating occasional adverse consequences regarding safety, health and environment in clinical laboratories. RESULTS: This article discusses the applicability, responsibilities, development and maintenance as well as their corresponding implications in laboratory procedures.

Indicadores de sustentabilidade em medicina laboratorial / Sustainability indicators in laboratory medicine

O artigo apresenta os princípios conceituais sobre desenvolvimento sustentável, sustentabilidade e avalia a evolução e os impactos na economia, no meio ambiente e na sociedade. Discutem-se a aplicabilidade dos conceitos de sustentabilidade empresarial na medicina laboratorial e os desafios inerentes à implantação no laboratório clínico. O impacto dos indicadores de sustentabilidade e seu papel no processo de gestão também são analisados criticamente sob a ótica do balanço socioambiental. O texto apresenta ainda algumas ferramentas para avaliação e interpretação dos indicadores e sua aplicação no processo de análise crítica. Finalmente, o artigo descreve a importância dos indicadores de sustentabilidade na prática do benchmarking e sua aplicabilidade no laboratório clínico.

The article presents the conceptual principles on sustainable development and sustainability. Furthermore, it evaluates the progress and impacts on the economy, environment and society. It discusses the applicability of the concepts of corporate sustainability in laboratory medicine and the challenges of deployment in the clinical laboratory. The impact of sustainability indicators and their role in management are also critically reviewed from the perspective of social and environmental balance. Additionally, the text provides some tools for evaluation and interpretation of indicators and their corresponding application in the critical analysis process. Lastly, the article describes the importance of sustainability indicators in the practice of benchmarking and its applicability in the clinical laboratory.

Perigos e riscos na medicina laboratorial: identificação e avaliação / Hazards and risks in laboratory medicine: identification and evaluation

Os perigos no ambiente de trabalho estão relacionados com qualquer tipo de fonte potencialmente danosa, em termos de lesões, ferimentos ou danos para a saúde ou uma combinação desses fatores. Os riscos são consequências dos perigos existentes no laboratório. Os laboratórios clínicos apresentam múltiplos riscos ocupacionais aos trabalhadores, categorizados como riscos biológicos, físicos, químicos, ergonômicos e para ocorrência de acidentes. É importante o laboratório identificar os riscos, avaliar os impactos que podem afetar o negócio e estabelecer critérios de priorização para a tomada de decisões, implementando estratégias e ações preventivas, a fim de evitar a instalação de falhas ou danos potenciais. Este artigo propõe uma sistemática de identificação e avaliação dos perigos e riscos em saúde e segurança ocupacional no laboratório clínico e discute suas aplicações na prática operacional.

Workplace hazards are related to any potentially harmful source in terms of lesions, injuries and health damage or a combination of these factors. The risks are consequences of laboratory hazards. Clinical laboratories pose multiple occupational hazards, which are categorized as biological, physical, chemical, ergonomic and accident prone. It is important to identify risks, assess the impacts that may affect the enterprise and establish prioritization criteria for making decisions. Furthermore, it is essential to implement strategies and preventive actions in order to avoid flaws or potential damage. Not only does this article propose a systematic identification and assessment of hazards, health risks and occupational safety within clinical laboratories, but it also discusses their applications in operational practice.